Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

180
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
180

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World Study.

Journal of clinical medicine·2026
Same author

Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Defining a critical therapeutic window: cyclosporine exposure in months 1-2 as a determinant of acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation from matched related donors.

Annals of hematology·2026
Same author

Management of Rituximab-Associated Hypersensitivity Reactions with Successfully Applied Desensitization Protocols: A Clinical Experience of 46 Infusions in 11 Patients.

Journal of clinical medicine·2026
Same author

Time-Dependent Prognostic Value of the mEASIX Score in Patients with Myelodysplastic Syndromes.

Diagnostics (Basel, Switzerland)·2026
Same author

Clinical outcomes and prognostic factors in hematologic malignancy patients with probable CMV pneumonia.

BMC infectious diseases·2026

Related Experiment Video

Updated: Jul 29, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.

Elif Birtas Atesoglu1, Zafer Gulbas2, Ant Uzay3

  • 1Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey.

Hematological Oncology
|May 22, 2023
PubMed
Summary

This study evaluated glofitamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in Turkey. Real-world data showed promising overall survival, but toxicity remains a concern.

Keywords:
bispecific antibodiesglofitamabrelapsed/refractory diffuse large B-cell lymphoma

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Experiment Videos

Last Updated: Jul 29, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Glofitamab, a CD3xCD20 bispecific antibody, shows promise in clinical trials for B-cell lymphomas.
  • Real-world data for glofitamab in diffuse large B-cell lymphoma (DLBCL) patients, especially those with extensive prior treatment, is limited.
  • Understanding outcomes in a broader, unselected patient population is crucial for treatment guidance.

Purpose of the Study:

  • To assess the real-world effectiveness and safety of glofitamab in patients with relapsed/refractory (R/R) DLBCL.
  • To evaluate treatment outcomes, including response rates, survival, and toxicity, in a Turkish patient cohort.
  • To provide insights into the use of glofitamab in a heavily pretreated, diverse patient population.

Main Methods:

  • Retrospective analysis of 43 R/R DLBCL patients treated with glofitamab via compassionate use across 20 centers in Turkey.
  • Data collection included patient demographics, prior treatments, treatment response, survival, and adverse events.
  • Median follow-up was 5.7 months.

Main Results:

  • Overall response rate (complete + partial) was 37% in efficacy-evaluable patients.
  • Median progression-free survival (PFS) was 3.3 months and median overall survival (OS) was 8.8 months.
  • Hematological toxicity was the most frequent adverse event; treatment-related mortality occurred in 3 patients (cytokine release syndrome, febrile neutropenia).

Conclusions:

  • Glofitamab demonstrated a median OS of approximately 9 months in a heavily pretreated R/R DLBCL population, suggesting potential benefit.
  • Real-world effectiveness is encouraging, but careful monitoring for toxicities, particularly hematological events and cytokine release syndrome, is essential.
  • This study represents the largest real-world evaluation of glofitamab in R/R DLBCL, highlighting the need for continued safety surveillance.